Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Inclusion Criteria: * Age equal or greater than 18 years old and willing to give their signed consent * Histologically or cytologically confirmed non-squamous, non-small cell lung cancer * Locally advanced or metastatic disease, not amenable to curative surgery or radiotherapy * Patients must have one of the following: * NSCLC which harbors EGFR Exon 19 deletion. * NSCLC which harbors EGFR L858R mutation. * NSCLC which harbors EGFR G719X, S768X, L861X mutation, and other activating uncommon mutations in exon 18-21 * NSCLC which harbors EGFR exon20 insertion * NSCLC which harbors EGFR T790M mutation EGFR deletion/mutation must be documented by a Clinical Laboratory Improvement Amendments (CLIA) certified test * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * At least one target lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline at equal or greater than 10 mm in the longest dimension by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * Patients must have received at least one line of EGFR tyrosine kinase inhibitor (TKI) treatment, if an Food and Drug Administration (FDA)-approved treatment exist for the EGFR mutation. Patients whose tumor harboring EGFR T790M mutation must have received prior osimertinib (or another EGFR TKI with demonstrated activity against T790M mutation). Patients who received more than one EGFR TKIs are eligible. Up to two lines …